The U.S. Health and Human Services Department (HHS) announced late this morning that it will delay, from this coming Monday, March 22 until July 20, the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program.
The Biden administration is perceived to be sympathetic to the health centers’ concerns and it may decide to scrap the rule altogether. It has withdrawn or delayed a number of last-minute Trump administration health care rules. HHS’s Health Resources and Services Administration’s Administrative Dispute Resolution rule is an exception. Biden has received some criticism from conversative media and conservative interest groups for delaying what they argue would be a cost saver for patients. Health centers strongly disagree that the rule would benefit patients.
The U.S. Health and Human Services Department (HHS) announced late this morning that it will delay, from this coming Monday, March 22 until July 20, the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.